奧翔藥業(603229.SH):8835萬元競得浙江頭門港經濟開發區一宗工業用地
格隆匯1月20日丨奧翔藥業(603229.SH)公佈,近期,公司按照相關法律規定和法定程序參與了浙江頭門港經濟開發區南洋八路與東海第七大道交叉口東南角地塊使用權的掛牌出讓競拍,最終以8835萬元人民幣競得上述地塊149970平方米的國有建設用地使用權,並與臨海市自然資源和規劃局簽署了《國有建設用地使用權出讓合同》,合同編號:3310822020A21049。
土地位置:浙江頭門港經濟開發區南洋八路與東海第七大道交叉口東南角;土地面積:149970平方米;土地用途:工業用地;出讓年限:50年;土地價格:8835萬元人民幣。
此次購買土地使用權是基於公司未來經營發展需要,用於提升未來CDMO業務以及“特色原料藥及關鍵中間體+製劑”的一體化業務產能,增強公司持續發展能力,提升公司行業競爭力,符合公司戰略佈局和長遠發展目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.